Environment-Wide Association Study of Cognitive Function in U.S. Older Adults using the NHANES Data

- 3
- 4 HyunA Jang,¹ Jiyun Lee,^{1,*} Vy Kim Nguyen,² and Hyeong-Moo Shin¹
- 5
- ¹Department of Environmental Science, Baylor University, Waco, TX, USA
- ⁷ ²Department of Biomedical Informatics, Medical School, Harvard University, Boston, MA, USA
- 8
- 9 * Address correspondence to
- 10 Jiyun Lee, Ph.D.
- 11 Department of Environmental Science, Baylor University, Waco, TX, USA
- 12 E-mail: Jiyun_Lee@baylor.edu

13 Abstract

14 Neurodegenerative diseases pose increasing challenges to global aging populations. Cognitive decline in older adults is an initial indicator of neurodegenerative diseases, yet 15 comprehensive research on environmental chemical exposures related to cognitive decline is 16 limited. This study uses Environment-Wide Association Study (EWAS) framework to investigate 17 associations of environmental chemicals with cognitive function in individuals aged ≥ 60 years. 18 We used the Digit Symbol Substitution Test (DSST) scores (lower scores indicate cognitive 19 decline) and chemical biomarker data of the U.S. National Health and Nutrition Examination 20 Survey (NHANES) spanning four cycles (1999-2000, 2001-2002, 2011-2012, 2013-2014). We 21 conducted multiple survey-weighted regression to identify biomarkers associated with DSST 22 scores, penalized logit regression to estimate odds ratio (OR) of cognitive decline with identified 23 biomarkers, and correlation network analyses to examine relationships among identified 24 biomarkers and cognitive decline. After correction for multiple comparisons, 27 out of 173 25 biomarkers having a $\geq 10\%$ detection rate were associated with DSST scores (q-value <0.05). 26 Among them, increased odds of cognitive decline were associated with elevated levels of blood 27 lead (Pb) (OR = 1.12, 95% CI: 1.01,1.42), blood 1,4-dichlorobenzene (1,4-DCB) (OR = 1.34, 95% 28 CI: 1.17, 1.54), and urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) (OR = 1.34, 29 95% CI: 1.10, 1.62). Correlation network showed biomarkers that potentially impact cognitive 30 decline upon related health conditions, such as stroke. In conclusion, leveraging the EWAS 31 framework enables us to identify chemical biomarkers that were not previously discovered from 32 traditional approaches of examining a small number of chemicals at a time. While our findings 33 provide foundation for further research, longitudinal studies are warranted to elucidate causal 34 35 relationships.

2

36

37 Keywords

- 38 Chemical exposure; Cognitive function; Environment-Wide Association Study (EWAS);
- 39 National Health and Nutrition Examination Survey (NHANES); Older adults

40 Introduction

41	Increasing incidence of neurodegenerative diseases poses a prominent challenge in
42	societies experiencing global population aging. ¹ In the United States (U.S.) alone, more than 6.2
43	million people were affected by neurodegenerative diseases in 2022, including Alzheimer's
44	disease. ² These diseases accounted for approximately 300,000 deaths and 3 million disability-
45	adjusted life years (DALYs) during 1990-2016. ³⁻⁵ The prevalence of clinical Alzheimer's disease
46	among adults aged 65 years and older is projected to increase from 7.2 million in 2025 to 13.9
47	million in 2060. ⁶ In 2021, the U.S. incurred an annual cost of over \$355 billion due to
48	Alzheimer's disease and related dementias, and this societal burden is expected to increase due to
49	the increased health care cost. ⁷ Consequently, there is growing attention towards the
50	identification of risk factors and treatment development for neurodegenerative diseases. ⁸
51	Neurodegenerative diseases are characterized by the progressive loss of neurons, leading
52	to deterioration in both the structure and function of neural networks. ⁹ This deterioration
53	ultimately leads to impaired cognitive function. ^{1,10} Gradual cognitive decline in old age is
54	typically limited to subtle declines that evolve slowly over the years, attributed to normative
55	developmental processes. ^{11,12} Conversely, mild or precipitous declines in cognitive function can
56	lead to pathological processes underlying Alzheimer's disease and related dementias. ^{11,13} Thus,
57	early detection of changes in cognitive function, such as mild cognitive impairment, enables
58	timely diagnosis and treatment of neurodegenerative diseases, potentially delaying disease
59	progression. ^{13,14}

The risk of cognitive decline generally increases due to a combination of genetic and
non-genetic factors. Age and genetic factors, including family history and susceptibility genes
such as the apolipoprotein E ε4 allele, are the most significant contributors to cognitive

4

decline.^{15,16} Other well-known non-genetic risk factors include comorbidities (hypertension,
diabetes, stroke), unhealthy diet, physical inactivity, smoking, and alcohol consumption.^{17,18}
These risk factors could influence the susceptibility of individual's cognitive function (e.g.,
disease onset, timing, severity) by interacting with genetic factors.^{16,19,20} Therefore, identifying
and understanding modifiable risk factors of cognitive decline could be a proactive approach to
promoting cognitive health.^{17,21}

Several studies have assessed associations between exposures to environmental 69 chemicals and cognitive decline in specific populations. For example, exposures to metals, 70 typically manganese (Mn),²²⁻²⁴ cadmium (Cd),²⁴⁻²⁷ lead (Pb),²⁵⁻²⁷ barium (Ba),²⁴ cobalt (Co),²⁴ 71 cesium (Cs),²⁴ and thallium (TI)²⁴ were reported to increase the risk of low cognitive 72 performance. In addition, higher urinary 3-phenoxybenzoic acid concentrations in adults were 73 associated with cognitive dysfunction²⁸ and it was observed that butyl benzyl phthalate is a 74 potential cognitive-disrupting compound.²⁹ However, previous studies examined exposure to a 75 small number of chemicals or compounds individually in association with cognitive function. In 76 77 addition, they are neither systematic nor comprehensive.

Environmental-Wide Association Studies (EWAS), derived from Genome-Wide 78 Association Studies (GWAS), are a useful approach for systematically and comprehensively 79 evaluating associations between hundreds of environmental factors and health outcomes.³⁰ While 80 GWAS aim to identify genetic factors associated with diseases of interest, EWAS focus on 81 assessing environmental factors. Over the past decade, several EWAS studies have been 82 conducted to elucidate the relationship between environmental chemical exposures and health 83 outcomes.³¹ Frequently-studied health outcomes were type 2 diabetes, ^{30,32,33} obesity, ^{34,35} and 84 blood pressure.^{36,37} Other outcomes included liver enzymes,³⁸ mental and social well-being,³⁹ 85

86	testosterone deficiency, ⁴⁰ diabetic retinopathy, ⁴¹ multiple sclerosis, ⁴² peripheral arterial disease, ⁴³
87	and cardiovascular disease. ⁴⁴ However, no studies have simultaneously and comprehensively
88	examined environmental chemical exposures associated with cognitive decline in older adults.
89	This study aims to identify environmental chemical biomarkers associated with cognitive
90	decline in U.S. older adults by using the EWAS approach and the National Health and Nutrition
91	Examination Survey (NHANES) data. First, to screen chemicals or their biomarkers, we
92	examined a single association for each biomarker and identified those that were statistically
93	significant after controlling for multiple comparisons. Second, we evaluated the effects of
94	multiple exposures to those identified biomarkers on cognitive decline. Finally, we extracted a
95	correlation network structure to explore potential pathways between chemical exposures and
96	cognitive decline and further assessed the potential mediating effect of other modifiable factors.
97	
97 98	2. Methods
97 98 99	2. Methods 2.1. Study population
97 98 99 100	 2. Methods 2.1. Study population NHANES is conducted every two years in the U.S. by the Centers for Disease Control
97 98 99 100 101	 2. Methods 2.1. Study population NHANES is conducted every two years in the U.S. by the Centers for Disease Control and Prevention (CDC) and the National Centers for Health Statistics (NCHS). This is a cross-
97 98 99 100 101 102	2. Methods 2. Methods 2.1. Study population NHANES is conducted every two years in the U.S. by the Centers for Disease Control and Prevention (CDC) and the National Centers for Health Statistics (NCHS). This is a cross- sectional survey designed to assess the health and nutritional status of both adults and children.
97 98 99 100 101 102 103	2. Methods 2.1. Study population NHANES is conducted every two years in the U.S. by the Centers for Disease Control and Prevention (CDC) and the National Centers for Health Statistics (NCHS). This is a cross- sectional survey designed to assess the health and nutritional status of both adults and children. To obtain a representative sample of the U.S. population, complex, multi-stage, and probability
97 98 99 100 101 102 103 104	2. Methods 2. Methods 2. Nethods DIVENTIAL Conducted every two years in the U.S. by the Centers for Disease Control and Prevention (CDC) and the National Centers for Health Statistics (NCHS). This is a cross- sectional survey designed to assess the health and nutritional status of both adults and children. To obtain a representative sample of the U.S. population, complex, multi-stage, and probability sampling techniques are used. NHANES data are publicly available (at
97 98 99 100 101 102 103 104 105	2. Methods 2. Methods 2.1. Study population NHANES is conducted every two years in the U.S. by the Centers for Disease Control and Prevention (CDC) and the National Centers for Health Statistics (NCHS). This is a cross- sectional survey designed to assess the health and nutritional status of both adults and children. To obtain a representative sample of the U.S. population, complex, multi-stage, and probability sampling techniques are used. NHANES data are publicly available (at https://www.cdc.gov/nchs/nhanes) and include individual questionnaires, physical examinations,
97 98 99 100 101 102 103 104 105 106	2. Methods 2.1. Study population NHANES is conducted every two years in the U.S. by the Centers for Disease Control and Prevention (CDC) and the National Centers for Health Statistics (NCHS). This is a cross- sectional survey designed to assess the health and nutritional status of both adults and children. To obtain a representative sample of the U.S. population, complex, multi-stage, and probability sampling techniques are used. NHANES data are publicly available (at <u>https://www.cdc.gov/nchs/nhanes</u>) and include individual questionnaires, physical examinations, and laboratory tests. More details on the design and methods of the NHANES data are available

- 108 Our study combined data from four cross-sectional surveys conducted in 1999-2000,
- 109 2000-2001, 2011-2012, and 2013-2014, each of which included assessments of cognitive
- function. Targeting older adults (age ≥ 60 years), our analysis consisted of 4,970 individuals after
- excluding those with missing cognitive function data (n = 34,774) and those with abnormal
- 112 urinary creatinine levels (n = 1,191) (Figure 1). The NCHS Ethics Review Board has approved
- this survey (Protocol #98-12 for NHANES 1999-2002 data, Protocol #2011-17 for NHANES
- 114 2011-2014 data), and all participants completed informed consent forms.



National Health and Nutrition Examination Survey (NHANES) Data

Figure 1. The process of data integration, non-targeted screening, and extended analysis. Data
from four cycles of the National Health and Nutrition Examination Survey (NHANES) were
used in this study. Final study subjects and environmental factors included in this study were
selected based on specified inclusion and exclusion criteria.

121 2.2. Cognitive function assessment

122

115

In NHANES, the Digit Symbol Substitution Test (DSST), a subscale of the Wechsler

123 Adult Intelligence Scale, was utilized to evaluate primary cognitive processing speed, attention,

124 and working memory.⁴⁶ Its application aids in determining the presence of cognitive dysfunction

across various stages, including preclinical, prodromal, and dementia phases.^{47,48} Administered in

126	a paper-and-pencil format, this cognitive test requires individuals to match symbols to
127	corresponding numbers based on a provided key. ⁴⁹ The score is the total number of correct
128	matches within 90 to 120 seconds, with lower scores indicating diminished cognitive function. ⁴⁹
129	Since 1999, NHANES has administered this test in participants aged 60 years and older. This test
130	occurs during face-to-face interviews at the Mobile Examination Center by trained interviewers.
131	Participants have the option to select from English, Spanish, Korean, Vietnamese, or Chinese. In
132	this study, we used DSST z-scores when screening chemical biomarkers related to cognitive
133	function and DSST raw scores below the 25 th percentile when defining as cognitive decline, as
134	used by NCHS reports ⁵⁰ and other previous studies. ^{51,52}

135

136 2.3. Measurement of environmental chemical biomarkers

In NHANES, environmental chemical biomarker data were collected from the blood and 137 urine samples of randomly selected participants within specific age groups in a one-third sample. 138 Because detailed biological sample collection methods from NHANES participants vary by 139 cycle,⁵³⁻⁵⁶ we used a harmonized and unified version of the NHANES chemical biomonitoring 140 data.⁵⁷ A total of 381 environmental chemical biomarkers were examined across the four cycles. 141 These chemicals could be grouped as follows: acrylamide (n = 2), aldehydes (n = 13), aromatic 142 amines (n = 16), dietary components (n = 6), dioxins (n = 14), furans (n = 20), metals (n = 29), 143 per- and polyfluoroalkyl substances (PFAS) (n = 11), personal care & consumer product 144 compounds (PCCPCs) (n = 12), pesticides (n = 55), phosphate flame retardants (PFR) (n = 9), 145 phthalates & plasticizers (n = 14), polyaromatic hydrocarbons (PAHs) (n = 12), polychlorinated 146 biphenyls (PCBs) (n = 70), smoking-related compounds (SRCs) (n = 15), and volatile organic 147 148 compounds (VOCs) (n = 83). Detailed information, including the number of observations,

149 detection rate, and lower limit of detection (LLOD) value, is given in Table S1 of Supplementary Information. In NHANES, all chemical biomarker concentrations below the LLOD were 150 replaced with the LLOD/ $\sqrt{2}$. The distribution of each biomarker concentration is provided in 151 152 Table S2. The NHANES website offers detailed laboratory measurement methods and quality control procedures (https://wwwn.cdc.gov/nchs/nhanes/). 153 154 155 2.4. Covariates 156 We selected 11 covariates which are potential confounding or risk factors for cognitive 157 decline identified in previous studies: sex (men and women), age group (60-64, 65-69, 70-74, 75-79, and \geq 80 years), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican 158 American/Hispanic, and others), marital status (married or living with partner, never married, 159 divorced or separated, and widowed), education level (<high school, high school, and >high 160 school), body mass index (<25, 25-<30, 30-<40, and \geq 40 kg/m²),⁵⁸ cotinine level as a proxy of 161 smoking status (<3 and \geq 3 ng/mL),⁵⁹ alcohol consumption (non-drinker and drinker), health 162 conditions (hypertension, diabetes, and stroke). Alcohol consumption and health conditions were 163 ascertained by self-reported questionnaires (variable name in NHANES): "Had at least 12 164 alcohol drinks/lifetime? (ALQ110)", "Ever told you had high blood pressure? (BPQ020)", "Ever 165 166 told you have diabetes? (DIO010)" and "Ever told you had a stroke? (MCO160f)". 167 168 2.5. Statistical analysis

Descriptive statistics of participant characteristics were summarized using mean ±
 standard deviation (SD), number of cases (n), and percentage (%). The differences in DSST
 scores among each covariate were compared using t-tests and ANOVA. A cognitive decline

group (i.e., participants with the lowest 25th percentile DSST scores) and a normal group (i.e., the rest as a reference) were compared using the chi-squared test. All analyses were performed using R version 4.3.1 (R Core Team, <u>https://www.R-project.org/</u>). The critical level of significance was set at $\alpha = 0.05$.

2.5.1. Screening environmental chemical biomarkers related to cognitive function scores

178 To screen hundreds of chemical biomarkers that are associated with lower DSST z-scores, 179 we performed an EWAS non-targeted screening approach and identified biomarkers potentially 180 affecting cognitive function. During this step, we used complete-cases data without missing values and considered chemicals with a detection rate of $\geq 10\%$. All concentrations were log10-181 transformed to control a right-skewed distribution and z-standardized. We explored the 182 association between each biomarker and DSST z-scores using multiple survey-weighted 183 184 regression adjusted for all covariates. To account for the complex survey design, we calculated sample weights following the NHANES guidelines.⁶⁰ *P*-values were corrected using the false 185 186 discovery rate (FDR, q-value) (Figure 1).

187

177

188 2.5.2. Associations between exposure to identified biomarkers and cognitive decline

After identifying chemical biomarkers associated with DSST z-scores from the first step (*q*-value <0.05), we divided our participants into two groups (a normal group *vs*. a cognitive decline group) and examined associations of chemical exposures with cognitive decline by only including the identified chemical biomarkers with a detection rate of \geq 50% and variance inflation factor (VIF) <10 in the model. We employed a multivariate imputation by chained equations (MICE) technique assuming 'missing-at-random (MAR)' to create 10 imputed

datasets.⁶¹ To reduce imputation bias due to temporal trends in chemical biomarker, we generated
imputed data separately for each of the 1999-2002 and 2011-2014 cycles and estimated the odds
ratio (OR) and 95% confidence intervals (CI) of cognitive decline associated with biomarker
levels using penalized logit regression with the Akaike Information Criterion (AIC) adjusted for
all covariates.

200

2.5.3. Interactive impact of chemical biomarkers and selected covariates on cognitive decline 201 To uncover the interactive impact of identified chemical biomarkers and the selected 202 covariates on cognitive decline, we first combined imputed data from both the 1999-2002 and 203 2011-2014 cycles, focusing solely on chemical biomarkers consistently measured across all 204 cycles. Next, we utilized Gaussian Graphical Models (GGMs) with the desparsified Lasso to 205 206 derive a partial correlation network structure encompassing the identified chemical biomarkers, cognitive decline, and all covariates. Significant *p*-values were adjusted using the Holm– 207 Bonferroni method. We selected non-chemical factors exhibiting statistically significant 208 209 correlation coefficients with cognitive decline. Finally, we conducted stratified analyses on each category of the non-chemical factors to assess their potential as mediators using logistic 210 regression adjusted for other covariates. 211

212

213 **3. Results**

214 3.1. Characteristics of study participants

Overall, 4,970 participants were included in this study, with 1,305 participants classified as the cognitive decline group. Significant differences in DSST z-scores were observed across all covariates (Table 1). Men had lower DSST z-scores than women, and Mexican

- 218 Americans/Hispanics or widowed individuals had the lowest z-scores. DSST z-scores tended to
- 219 decrease with increasing age or lower education levels. Smokers scored lower than non-smokers,
- 220 whereas participants who consumed alcohol scored higher than those who never drank alcohol.
- 221 No trend was observed with changes in BMI.

				Cognitiv	e decline ^a	
	Digit Symbol	Substitution Te	st (DSST)	Cognitive	Cognitive	
		scores		normality	decline	<i>p</i> -value ^c
				(n = 3,665)	(n = 1,305)	
	n (%)	Mean \pm SD	<i>p</i> -value ^b	n (%)	n (%)	
Sex			< 0.001			< 0.001
Men	2,545 (51.2)	41.6 ± 17.2		1,805 (49.2)	740 (56.7)	
Women	2,425 (48.8)	45.6 ± 18.7		1,860 (50.8)	565 (43.3)	
Age (years)			< 0.001			< 0.001
60-64	1,441 (29.0)	49.5 ± 18.7		1,177 (32.1)	264 (20.2)	
65-69	1,070 (21.5)	45.0 ± 18.0		814 (22.2)	256 (19.6)	
70-74	946 (19.0)	42.9 ± 17.1		705 (19.2)	241 (18.5)	
75-79	605 (12.2)	38.9 ± 16.3		409 (11.2)	196 (15.0)	
Over 80	908 (18.3)	36.2 ± 15.4		560 (15.3)	348 (26.7)	
Body mass index (BMI, kg/m ²)	· · ·		< 0.001			< 0.001
Underweight or normal (BMI	1 202 (26 0)	10 E · 10 4		046 (25.9)	247(26.6)	
<25)	1,293 (26.0)	43.5 ± 18.4		946 (25.8)	347 (26.6)	
Overweight (25 ≤ BMI < 30)	1,847 (37.2)	43.6 ± 17.9		1,377 (37.6)	470 (36.0)	
Obesity (30< BMI <40)	1,456 (29.3)	44.3 ± 17.9		1,093 (29.8)	363 (27.8)	
Severe obesity (BMI >40)	233 (4.7)	44.7 ± 17.4		179 (4.9)	54 (4.1)	
Unknown	141 (2.8)	33.5 ± 16.1		70 (1.9)	71 (5.4)	
Race/ethnicity			< 0.001			< 0.001
Non-Hispanic white	2,626 (52,8)	48.5 ± 16.8		2,212 (60.4)	414 (31.7)	
Non-Hispanic black	986 (19.8)	37.3 ± 16.8		599 (16.3)	387 (29.7)	
Mexican American/Hispanic	1.062 (21.4)	35.7 ± 17.7		609 (16.6)	453 (34.7)	
Others	296 (6.0)	48.8 ± 17.8		245 (6.7)	51 (3.9)	
Marital status	_, • (••••)		< 0.001			< 0.001
Married or living with partner	2.951 (59.4)	45.8 ± 17.9		2.294 (62.6)	657 (50.3)	
Never married	203 (4.1)	43.2 + 18.7		142 (3.9)	61 (4.7)	
Divorced or separated	681 (13.7)	43.1 + 18.1		487 (13 3)	194 (14 9)	
Widowed	1 026 (20 6)	383 + 171		664 (18.1)	362(27.7)	
Unknown	100 (2.2)	37.0 ± 18.2		78 (2,1)	31(24)	
	109 (2.2)	57.0 ± 16.2	.0.001	78 (2.1)	51 (2.4)	-0.001
Education level	1 (07 (22 2)	20.0 15.2	<0.001		0.41 (c.4.4)	< 0.001
< High school	1,607 (32.3)	30.9 ± 15.3		766 (20.9)	841 (64.4)	
High school	1,1/3 (23.6)	44.8 ± 15.9		921 (25.1)	252 (19.3)	
> High school	2,182 (43.9)	52.3 ± 15.4		1,975 (53.9)	207 (15.9)	
Unknown	8 (0.2)	29.4 ± 18.6		3 (0.1)	5 (0.4)	
Cotinine level as a proxy of			< 0.001			< 0.001
smoking status (ng/mL)		44 5 10 1	-	0.064 (00.0)	040 (72 5)	-
Low (<3)	3,912 (78.7)	44.5 ± 18.1		2,964 (80.9)	948 (72.6)	
High (≥ 3)	789 (15.9)	40.3 ± 17.5		526 (14.4)	263 (20.2)	
Unknown	269 (5.4)	38.9 ± 17.6	0.004	175 (4.8)	94 (7.2)	0.001
Alcohol consumption		20 5 15 5	< 0.001		0.51 (20.0)	< 0.001
Non-drinker	797 (16.0)	39.5 ± 17.7		526 (14.4)	271 (20.8)	
Drinker	877 (17.6)	42.3 ± 17.8		645 (17.6)	232 (17.8)	
Unknown	3,296 (66.3)	44.9 ± 18.0		2,494 (68.0)	802 (61.5)	
Health conditions						
Ever told you had high blood						0.000
_ · · · · · · · · · · · · · · · · · · ·			< 0.001			0.009

Table 1. Characteristics of the National Health and Nutrition Examination Survey (NHANES) study participants (1999-2000, 2001-2002, 2011-2012, and 2013-2014) included in this study (total = 4,970).

2,833 (57.0)	42.3 ± 17.6		2 022 (55 2)	011 ((0 1)	
8 (0 2)			2,022 (33.2)	811 (62.1)	
8 (0.2)	43.6 ± 25.2		6 (0.2)	2 (0.2)	
		< 0.001			< 0.001
3,779 (76.0)	44.7 ± 18.3		2,875 (78.4)	904 (69.3)	
1,007 (20.3)	38.9 ± 17.0		654 (17.8)	353 (27.0)	
184 (3.7)	44.9 ± 15.6		136 (3.7)	48 (3.7)	
		< 0.001			< 0.001
4,630 (93.2)	44.2 ± 18.0		3,476 (94.8)	1,154 (88.4)	
330 (6.6)	34.2 ± 16.4		181(4.9)	149 (11.4)	
10 (0.2)	44.6 ± 13.9		8 (0.2)	2 (0.2)	
	8 (0.2) 3,779 (76.0) 1,007 (20.3) 184 (3.7) 4,630 (93.2) 330 (6.6) 10 (0.2)	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

^a Cognitive decline was defined as less than the 25th percentile of Digit Symbol Substitution Test 224 (DSST) raw scores. 225

226

^b *p*-value was estimated using t-test or ANOVA. ^c *p*-value was estimated using the Chi-square test. 227

228 3.2. Identified chemical biomarkers related to cognitive function test scores

- 229 Out of 381 environmental chemical biomarkers examined across all four NHANES
- 230 cycles, we only evaluated 173 biomarkers with a detection rate of $\geq 10\%$ (Figure 1). Among the
- 173 chemicals, 27 were associated with DSST z-scores (q-value < 0.05). These included metals
- 232 (n = 11), PAHs (n = 3), PCBs (n = 3), pesticides (n = 3), phthalates (n = 2), and one each of
- 233 PCCPCs, phytoestrogens, VOCs, flame retardants, and SRCs (Figure 2). PAHs, PCBs, phthalates,
- 234 SRCs, and VOCs each decreased DSST z-scores, whereas flame retardants, PCCPCs, and
- phytoestrogens increased the scores. Metals and pesticides had varying effects depending on the
- biomarker (Table S3). For example, per 1 standard deviation increase in log10-transformed blood
- lead (Pb) level, DSST z-scores decreased by 0.09.



238



- z-scores. Significant chemical biomarkers were dotted above the grey dashed line (q-value <0.05), and the arrows indicated the
- direction of their effects on DSST z-scores. Abbreviation: B, blood; DDT, dichlorodiphenyltrichloroethane; NNAL, 4-
- 242 (methylnitrosamino)-1-(3-pyridyl)-1-butanol; PCB, polychlorinated biphenyl; U, urine.

243 3.3. Associations between exposure to identified chemicals and cognitive decline

244	After screening chemical biomarkers that were associated with DSST z-scores, we
245	examined associations between the identified biomarkers and cognitive decline by restricting
246	analyses to those with a detection rate of \geq 50% and separating the entire data to 1999-2002 and
247	2011-2014 cycles. When using the data collected during the 1999-2002 cycle, we could evaluate
248	only 8 out of the 27 identified biomarkers, because the other 19 biomarkers were not measured
249	during this cycle or had detection rates below 50%. From this cycle, blood Pb increased the odds
250	of having cognitive decline (OR = 1.12, 95% CI: 1.01, 1.42), whereas blood cadmium (Cd)
251	decreased the odds (OR = 0.78 , 95% CI: 0.64, 0.96) (Table 2). From the 2011-2014 cycle data,
252	we evaluated 18 biomarkers after excluding those that were not measured during this cycle or
253	highly correlated chemicals with a VIF >10. From this cycle, blood 1,4-DCB and urinary 4-
254	(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) increased the odds of having cognitive
255	decline (OR = 1.34, 95% CI: 1.17, 1.54 and OR = 1.34, 95% CI: 1.10, 1.62, respectively).

	NHANES 1999-2002	NHANES 2011-2014
	$(n = 1,641, Case^a = 693)$	$(n = 2,043, Case^a = 593)$
	OR (95% CI)	OR (95% CI)
Metals		
In blood		
Cadmium	$0.78 (0.64, 0.96)^{a}$	0.89 (0.57, 1.39)
Lead	$1.20(1.01, 1.42)^{a}$	0.997 (0.23, 4.27)
Methylmercury	b	0.83 (0.51, 1.35)
Total mercury	b	c
In urine		
Cesium	0.74 (0.07, 7.64)	0.39 (0.02, 6.22)
Thallium	1.04 (0.06, 18.16)	2.08 (0.13, 33.17)
Cadmium	b	1.34 (0.67, 2.67)
Dimethylarsonic acid	b	1.49 (0.40, 5.51)
Mercury	b	1.63 (0.47, 5.63)
Arsenobetaine	b	0.79 (0.26, 2.35)
Total arsenic	b	c
Phthalates in urine		
Mono-ethyl phthalate	1.14 (0.25, 5.28)	1.43 (0.31, 6.53)
Mono-benzyl phthalate	1.87 (0.77, 4.56)	1.27 (0.36, 4.46)
PAHs in urine		
2-naphthol	b	1.27 (0.06, 27.98)
2-fluorene	b	c
3-fluorene	b	0.79(0.23, 2.71)
PCBs in urine		
PCB 167	e	b
PCB 177	e	b
PCB 178	e	b
Pesticides in blood		
p.p'-DDT	2.23 (0.68, 7.36)	b
3-phenoxybenzoic acid	b	0.88 (0.04, 17.86)
Mirex	e	b
Others		
Blood 1,4-Dichlorobenzene	b	$1.34 (1.17, 1.54)^{a}$
Urinary Benzophenone-3	b	0.52(0.18, 1.52)
Urinary Diphenyl phosphate	b	0.43 (0.02, 9.25)
Urinary Enterodiol	1.23 (0.31, 4.92)	b
Urinary NNAL	b	$1.34(1.10, 1.62)^{a}$

Table 2. Associations between 27 identified environmental chemical biomarkers and cognitive
 decline by two combined cycles (NHANES 1999-2002 and 2011-2014) (total = 4,970).

258 Note: All biomarker concentrations were log10-transformed and scaled. The OR and 95% CI were

estimated using the penalized logistic regression model with the Akaike information criterion adjusted for
 sex, age group, body mass index, race/ethnicity, marital status, education level, smoking status based on

261 the cotinine level, alcohol consumption, and health conditions (diabetes, hypertension, and stroke).

262 Abbreviation: CI, confidence interval; DDT, dichlorodiphenyltrichloroethane; NNAL, 4-

263 (methylnitrosamino)-1-(3-pyridyl)-1-butanol; OR, odds ratio; PAH, polycyclic aromatic hydrocarbon;

264 PCB, polychlorinated biphenyl.

^a Defined as less than or equal to the 25^{th} percentile DSST scores.

^bNot measured in this cycle.

267 ^c Excluded due to multi-collinearity.
268 ^d *p*-value <0.05.
269 ^e Detection rate <50%.

270

271 3.4. Interactive impact of chemical exposures and health conditions on cognitive decline

Based on the partial correlation network structure newly created in the current study, 272 cognitive decline was directly associated with non-chemical factors, including smoking, obesity, 273 274 alcohol consumption, and health conditions (stroke, diabetes, and hypertension) (Figure 3). Environmental chemical exposures seemed to have indirect relationships with cognitive decline, 275 276 with health conditions serving as potential mediators. For instance, blood Cd was positively correlated with stroke which was also positively correlated with cognitive decline. Thus, we 277 conducted stratified analyses by the status of stroke, diabetes, hypertension, and obesity to 278 examine the potential interactive impact of health conditions. Overall, we observed no significant 279 associations from these analyses (Figure 4). However, the odds of having cognitive decline for 280 stroke cases tended to be higher than for non-cases with increased levels of blood Cd, blood Pb, 281 282 urinary thallium (Tl), urinary mono-ethyl phthalate (MEP), and urinary mono-benzyl phthalate 283 (MBzP). Similarly, the odds for diabetes cases tended to be higher than for non-cases with increased levels of blood Cd, urinary Tl, urinary cesium (Cs), urinary MEP, and urinary MBzP. 284 285 The odds for hypertension cases tended to be higher than for non-cases with increased levels of 286 urinary Tl. The odds for obesity cases tended to be higher than for non-cases with increased 287 levels of urinary Tl, urinary MEP, and urinary MBzP.



288

Figure 3. Partial correlation () network plot depicting the magnitude and direction of
 correlation coefficients among identified chemical biomarkers, cognitive decline, and selected
 covariates. Only chemical biomarkers or covariates with significant correlation coefficients with
 cognitive decline (adjusted *p*-value <0.05) are shown. Green lines indicate relatively strong
 correlation coefficients (| 0.5). Red numbers indicate positive correlations and blue numbers
 indicate negative correlations.



Figure 4. Odds ratio (OR) and 95% confidence interval (CI) of cognitive decline associated with six chemical biomarkers

295

identified from correlation network structure stratified by four health conditions (total = 4,970). All chemical biomarker
 concentrations were log 10-transformed and scaled.

299 **4. Discussion**

300	To the best of our knowledge, this study represents comprehensive and systematic
301	investigation into the association between environmental chemical exposures and cognitive
302	decline. By using the EWAS approach and the NHANES data, we screened 173 environmental
303	chemical biomarkers and identified those potentially related to cognitive decline. Additionally,
304	we estimated the odds of having cognitive decline from the identified biomarkers and
305	investigated previously undiscovered pathways linking chemical biomarkers to cognitive decline
306	by extracting a correlation network structure. This allowed us to understand that cognitive
307	decline can be worsened with increased chemical exposures among those with known risk
308	factors of cognitive decline.
309	Among 173 chemical biomarkers investigated in this study, we observed that 27
310	biomarkers were associated with DSST z-scores. Most of them were metals, PAHs, PCBs,
311	pesticides, and phthalates which are known to have neurotoxicity. ⁶²⁻⁶⁶ Because these are
312	characterized by persistence and bioaccumulation, ⁶⁷⁻⁷⁰ older adults might have been chronically
313	exposed throughout their lives.

When including all environmental chemical biomarkers identified from non-targeted 314 screening, we found that blood Pb, urinary NNAL, and urinary 1,4-DCB increased the odds of 315 316 cognitive decline. Previous studies have shown consistent results for the association between Pb exposure and cognitive function. For instance, each 1 µg/L increase in Pb concentration was 317 associated with a 1.08-point decrease in DSST scores among U.S. older adults.²⁶ For every 1 318 μ g/dL increase in Pb levels, the odds of low cognitive performance in older adults in the U.S. by 319 10%.²⁵ In addition, Pb, a ubiquitous environmental contaminant,⁷¹ is exposed primarily through 320 food, water, tobacco smoke, air, dust, and soil.⁷² When Pb enters our human body, over 90% is 321

accumulated in bones.⁷³ Thus, older adults have high levels of Pb in their bodies due to their long 322 lifespan.^{73,74} Pb can affect cognitive decline by disrupting neurotransmission⁷⁵ and promoting 323 oxidative stress⁷⁶ through altering the fluidity or permeability of cell membranes.⁷⁷ It also has 324 indirect effects due to its associations with hypertension and other cardiovascular diseases,⁷⁸ as 325 well as its long-term storage in bones.⁷⁹ Regarding NNAL, a previous study using NHANES data 326 in older adults found that the group with the highest urinary NNAL concentration had a 327 significantly lower DSST z-score by 0.19 compared to the lowest concentration group.⁸⁰ NNAL 328 is a reliable biomarker for nitrosamine ketone (NNK) exposure.⁸¹ NNK is present in the leaves of 329 Nicotiana tabacum grown in the U.S.⁸² and can be exposed directly or indirectly through 330 smoking,⁸³ a well-known risk factor of cognitive decline. This compound is known to increase 331 neurotoxicity by altering responses to centrally acting drugs, increasing susceptibility to 332 neurotoxins, and enhancing metabolism.⁸¹ Lastly, 1,4-DCB (or paradichlorobenzene) can be 333 easily encountered in our daily lives because it is an active ingredient in mothballs, deodorizers, 334 and fumigants.^{84,85} However, there have been no epidemiological studies on the relationship 335 336 between 1,4-DCB and cognitive function. Several *in vivo* studies have suggested its neurotoxic mechanism. This compound has central nervous system toxicity, causing oxidative damage and 337 trace element alterations in various tissues, as well as oxidative DNA damage, leading to 338 reported cognitive decline.^{84,86,87} 339

From our correlation network analysis showing several pathways between chemical biomarkers and cognitive decline, we observed that stroke had relatively strong correlation coefficients with both blood Cd and cognitive decline. This finding highlights the need of this network analysis because blood Cd had protective effects against cognitive decline when considering other identified environmental chemicals in the regression. Previous studies have

345 shown that exposure to Cd can impair cognitive performance both in isolated exposure scenarios and in combination with other environmental chemicals identified through EWAS screening.²⁴⁻²⁷ 346 It is also well known that Cd causes vascular damage and promotes atherosclerosis⁸⁸ by 347 generating reactive oxygen species, disrupting sulfhydryl homeostasis, and downregulating nitric 348 oxide.⁸⁹ Stroke affects cognitive domains such as attention, memory, and language. People who 349 had stroke commonly experience cognitive impairment and memory loss, making them highly 350 likely to develop dementia within one year of stroke onset.^{90,91} While our findings suggest that 351 the effects of Cd exposure on cognitive decline may vary by individual's health conditions, the 352 specific mechanisms underlying these pathways remain unclear. Further experimental 353 investigation is warranted to elucidate the mediating effects of these health conditions on the 354 association between Cd exposure and cognitive decline. 355

Our study has several limitations. Firstly, the cross-sectional nature of the NHANES data 356 precludes establishing causation from our findings. Secondly, chemical biomarker concentration 357 data were from a spot sample of each participant, so they may not represent individual's average 358 359 exposure over the lifetime of our participants. Thirdly, despite adjusting for confounders associated with cognitive decline based on previous studies, there may still be unmeasured 360 confounding variables influencing our effect estimates. Fourthly, there could be imputation bias 361 on the biomarker data because each NHANES cycle had a different list of chemical biomarkers 362 and only one third of samples from each cycle were used to assess chemical biomarker 363 364 concentrations. In addition, if the missing data mechanism of NHANES is non-random (i.e., missing not at random, MNAR), performing multiple imputation under the assumption of 365 missing at random (MAR) may produce biased estimates.⁹² Finally, the EWAS approach used in 366

this study cannot assess the effects of chemical mixtures, such as additive effects, synergism,potentiation, and antagonism.

369

370 5. Conclusions

In this study, we employed an EWAS approach to explore 173 environmental chemical 371 biomarkers in association with cognitive decline among U.S. older adults. From the regression 372 including all identified biomarkers significantly associated with cognitive decline, we observed 373 positive associations between cognitive decline and Pb, 1,4-DCB, and NNAL. From the 374 correlation network structure, Cd may increase the risk of stroke which is a risk factor of 375 cognitive decline. These findings suggest that combined and prolonged exposure to these 376 chemicals may worsen cognitive impairment in aging populations. Our study underscores the 377 complex interplay between exposure to environmental chemicals and cognitive function in older 378 adults, emphasizing the need for further research to elucidate causal mechanisms and effectively 379 guide public health interventions. 380

381

382 Funding

383 This research received no specific grant from any funding agency in the public,384 commercial, or not-for-profit sectors.

385

386 Author contributions

HyunA Jang: conceptualization, data curation, formal analysis, methodology, software,
visualization, and writing – original draft. Jiyun Lee: conceptualization, data curation,
methodology, visualization, validation, and writing – review & editing. Vy Kim Nguyen:

- 390 resources, data curation, and writing review & editing. **Hyeong-Moo Shin:** conceptualization,
- 391 supervision, validation, and writing review & editing.

392

393 Data availability

394 The data and R code can be shared upon request to the corresponding author.

395

396 Conflict of interest statement

397 The authors declare that they have no conflicts of interest.

398

399 **References**

Hou YJ, Dan XL, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease.
 Nat Rev Neurol. Oct 2019;15(10):565-581. doi:10.1038/s41582-019-0244-7

402 2. Alzheimer's Association. Alzheimer's Disease Facts and Figures. Vol. 20. 2024.
 403 Alzheimers Dement. chrome 404 extension://efaidnbmnnibpcajpcglclefindmkaj/<u>https://www.alz.org/media/documents/alzheimers</u>
 405 -facts-and-figures.pdf

Collaborators GBDD. Global, regional, and national burden of Alzheimer's disease and
other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* Jan 2019;18(1):88-106. doi:10.1016/S1474-4422(18)30403-4

409 4. Collaborators GBDMND. Global, regional, and national burden of motor neuron diseases
410 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*.
411 Dec 2018;17(12):1083-1097. doi:10.1016/S1474-4422(18)30404-6

5. Collaborators GBDPsD. Global, regional, and national burden of Parkinson's disease,
1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*.
Nov 2018;17(11):939-953. doi:10.1016/S1474-4422(18)30295-3

6. Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population
estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United
States (2020-2060). *Alzheimers Dement*. Dec 2021;17(12):1966-1975. doi:10.1002/alz.12362

418 7. 2021 Alzheimer's disease facts and figures. *Alzheimers Dement*. Mar 2021;17(3):327-406.
419 doi:10.1002/alz.12328

8. National institute of Health. Looking Forward: Opportunities to Accelerate Alzheimer's
and Related Dementias Research 2024. 13, Jun. 2024.
https://www.nia.nih.gov/sites/default/files/2022-07/fy24_alzheimers_bypassbudget.pdf

Wilson DM, 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM,
Dewachter I. Hallmarks of neurodegenerative diseases. *Cell*. Feb 16 2023;186(4):693-714.
doi:10.1016/j.cell.2022.12.032

10. Ullah MF, Ahmad A, Bhat SH, Abu-Duhier FM, Barreto GE, Ashraf GM. Impact of sex
differences and gender specificity on behavioral characteristics and pathophysiology of
neurodegenerative disorders. *Neurosci Biobehav Rev.* Jul 2019;102:95-105.
doi:10.1016/j.neubiorev.2019.04.003

430 11. Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA. Neurodegenerative basis
431 of age-related cognitive decline. *Neurology*. Sep 21 2010;75(12):1070-8.
432 doi:10.1212/WNL.0b013e3181f39adc

Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. *Clin Geriatr Med.*Nov 2013;29(4):737-52. doi:10.1016/j.cger.2013.07.002

Kelley BJ, Petersen RC. Alzheimer's disease and mild cognitive impairment. *Neurol Clin*.
Aug 2007;25(3):577-609, v. doi:10.1016/j.ncl.2007.03.008

437 14. Andrade C, Radhakrishnan R. The prevention and treatment of cognitive decline and
438 dementia: An overview of recent research on experimental treatments. *Indian J Psychiatry*. Jan
439 2009;51(1):12-25. doi:10.4103/0019-5545.44900

Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the
evidence on modifiable risk factors for cognitive decline and dementia: A population-based
perspective. *Alzheimers Dement*. Jun 2015;11(6):718-26. doi:10.1016/j.jalz.2015.05.016

Fan J, Tao W, Li X, et al. The Contribution of Genetic Factors to Cognitive Impairment
and Dementia: Apolipoprotein E Gene, Gene Interactions, and Polygenic Risk. *Int J Mol Sci.*Mar 7 2019;20(5)doi:10.3390/ijms20051177

- 446 17. Manuello J, Min JS, Mccarthy P, et al. The effects of genetic and modifiable risk factors
 447 on brain regions vulnerable to ageing and disease. *Nature Communications*. Mar 27
 448 2024;15(1)doi:ARTN 2576
- 449 10.1038/s41467-024-46344-2

18. Edwards Iii GA, Gamez N, Escobedo G, Jr., Calderon O, Moreno-Gonzalez I. Modifiable
Risk Factors for Alzheimer's Disease. *Front Aging Neurosci.* 2019;11:146.
doi:10.3389/fnagi.2019.00146

453 19. Sepulveda-Falla D, Velez JI, Acosta-Baena N, et al. Genetic modifiers of cognitive
454 decline in PSEN1 E280A Alzheimer's disease. *Alzheimers Dement*. Apr 2024;20(4):2873-2885.
455 doi:10.1002/alz.13754

456 20. Faouzi J, Tan M, Casse F, et al. Proxy-analysis of the genetics of cognitive decline in
457 Parkinson's disease through polygenic scores. *NPJ Parkinsons Dis.* Jan 4 2024;10(1):8.
458 doi:10.1038/s41531-023-00619-5

459 21. Council. WD. WDC Dementia Risk Reduction Statement. Accessed June 14, 2024.
 460 chrome-extension://efaidnbmnnibpcajpcglclefindmkaj/<u>https://s3-eu-west-</u>
 461 <u>1.amazonaws.com/media.dh.gov.uk/network/353/files/2015/01/WDC-supportive-statement-on-</u>
 462 risk-reduction-FINAL-FOR-PUBLICATION-BRANDED-150128-LM.pdf

- 463 22. Barahona AJ, Bursac Z, Veledar E, Lucchini R, Tieu K, Richardson JR. Relationship of Blood and Urinary Manganese Levels with Cognitive Function in Elderly Individuals in the 464 465 United States Race/Ethnicity, NHANES 2011-2014. by Toxics. Apr 14 2022;10(4)doi:10.3390/toxics10040191 466
- 467 23. Larvie DY, Erikson KM, Armah SM. Elevated whole blood manganese is associated with
 468 impaired cognition in older adults, NHANES 2013-2014 cycle. *Neurotoxicology*. Jul 2022;91:94469 99. doi:10.1016/j.neuro.2022.04.016

470 24. Wang X, Xiao P, Wang R, et al. Relationships between urinary metals concentrations and
471 cognitive performance among U.S. older people in NHANES 2011-2014. *Front Public Health*.
472 2022;10:985127. doi:10.3389/fpubh.2022.985127

Lu K, Liu T, Wu X, Zhong J, Ou Z, Wu W. Association between serum iron, blood lead,
cadmium, mercury, selenium, manganese and low cognitive performance in old adults from
National Health and Nutrition Examination Survey (NHANES): a cross-sectional study. *Br J Nutr.* Nov 28 2023;130(10):1743-1753. doi:10.1017/S0007114523000740

477 26. Sasaki N, Carpenter DO. Associations between Metal Exposures and Cognitive Function 478 in American Older Adults. Int J Environ Res Public Health. Feb 17 2022;19(4)doi:10.3390/ijerph19042327 479

480 27. Song S, Liu N, Wang G, et al. Sex Specificity in the Mixed Effects of Blood Heavy
481 Metals and Cognitive Function on Elderly: Evidence from NHANES. *Nutrients*. Jun 25
482 2023;15(13)doi:10.3390/nu15132874

483 28. Kim UJ, Hong M, Choi YH. Environmental Pyrethroid Exposure and Cognitive
484 Dysfunction in U.S. Older Adults: The NHANES 2001-2002. *Int J Environ Res Public Health*.
485 Nov 16 2021;18(22)doi:10.3390/ijerph182212005

Yu Y, Wang Y, Dong Y, et al. Butyl benzyl phthalate as a key component of phthalate
ester in relation to cognitive impairment in NHANES elderly individuals and experimental mice. *Environ Sci Pollut Res Int.* Apr 2023;30(16):47544-47560. doi:10.1007/s11356-023-25729-8

489 30. Patel CJ, Bhattacharya J, Butte AJ. An Environment-Wide Association Study (EWAS) on
490 type 2 diabetes mellitus. *PLoS One*. May 20 2010;5(5):e10746.
491 doi:10.1371/journal.pone.0010746

31. Zheng Y, Chen Z, Pearson T, Zhao J, Hu H, Prosperi M. Design and methodology
challenges of environment-wide association studies: A systematic review. *Environ Res.* Apr
2020;183:109275. doi:10.1016/j.envres.2020.109275

495 32. Hall MA, Dudek SM, Goodloe R, et al. Environment-wide association study (EWAS) for
496 type 2 diabetes in the Marshfield Personalized Medicine Research Project Biobank. *Pac Symp*497 *Biocomput.* 2014:200-11.

498 33. Patel CJ, Chen R, Kodama K, Ioannidis JP, Butte AJ. Systematic identification of
499 interaction effects between genome- and environment-wide associations in type 2 diabetes
500 mellitus. *Hum Genet*. May 2013;132(5):495-508. doi:10.1007/s00439-012-1258-z

501 34. Zhao J, Fan B, Huang J, et al. Environment- and epigenome-wide association study of 502 obesity in 'Children of 1997' birth cohort. *Elife*. May 19 2023;12doi:10.7554/eLife.82377

503 35. Uche UI, Suzuki S, Fulda KG, Zhou Z. Environment-wide association study on 504 childhood obesity in the U.S. *Environ Res.* Dec 2020;191:110109. 505 doi:10.1016/j.envres.2020.110109

36. New A, Bennett KP. A Precision Environment-Wide Association Study of Hypertension
via Supervised Cadre Models. *IEEE J Biomed Health Inform.* Mar 2020;24(3):916-925.
doi:10.1109/JBHI.2019.2918070

37. McGinnis DP, Brownstein JS, Patel CJ. Environment-Wide Association Study of Blood
Pressure in the National Health and Nutrition Examination Survey (1999-2012). *Sci Rep.* Jul 26
2016;6:30373. doi:10.1038/srep30373

512 38. Chi Y, Park JT, Na S, Kwak K. Environment-wide association study of elevated liver 513 enzymes: results from the Korean National Environmental Health Survey 2018-2022. *Ann Occup* 514 *Environ Med*. 2023;35:e27. doi:10.35371/aoem.2023.35.e27

515 39. Ni MY, Yao XI, Cheung F, et al. Determinants of physical, mental and social well-being:
516 a longitudinal environment-wide association study. *Int J Epidemiol*. Apr 1 2020;49(2):380-389.
517 doi:10.1093/ije/dyz238

40. Lopez DS, Wulaningsih W, Tsilidis KK, et al. Environment-wide association study to comprehensively test and validate associations between nutrition and lifestyle factors and testosterone deficiency: NHANES 1988-1994 and 1999-2004. *Hormones (Athens)*. Jun 2020;19(2):205-214. doi:10.1007/s42000-020-00179-w

41. Blighe K, Gurudas S, Lee Y, Sivaprasad S. Diabetic Retinopathy Environment-Wide
Association Study (EWAS) in NHANES 2005-2008. J Clin Med. Nov 12
2020;9(11)doi:10.3390/jcm9113643

42. Belbasis L, Bellou V, Tzoulaki I, Evangelou E. Early-Life Factors and Risk of Multiple Sclerosis: An MR-EWAS. *Neuroepidemiology*. 2020;54(6):433-445. doi:10.1159/000508229

43. Zhuang X, Ni A, Liao L, et al. Environment-wide association study to identify novel
factors associated with peripheral arterial disease: Evidence from the National Health and
Nutrition Examination Survey (1999-2004). *Atherosclerosis*. Feb 2018;269:172-177.
doi:10.1016/j.atherosclerosis.2018.01.006

44. Zhuang X, Guo Y, Ni A, et al. Toward a panoramic perspective of the association between
environmental factors and cardiovascular disease: An environment-wide association study from
National Health and Nutrition Examination Survey 1999-2014. *Environ Int.* Sep 2018;118:146153. doi:10.1016/j.envint.2018.05.046

Health and nutrition examination survey plan and operations, 1999-2010. National Center
 for Health Statistics (U.S.); 2013. <u>https://stacks.cdc.gov/view/cdc/21304</u>

537 46. Tulsky DS, Saklofske DH, Wilkins C, Weiss LG. Development of a general ability index
538 for the Wechsler Adult Intelligence Scale--Third Edition. *Psychol Assess*. Dec 2001;13(4):566-71.
539 doi:10.1037//1040-3590.13.4.566

47. Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive
composite: measuring amyloid-related decline. *JAMA Neurol*. Aug 2014;71(8):961-70.
doi:10.1001/jamaneurol.2014.803

48. Amieva H, Meillon C, Proust-Lima C, Dartigues JF. Is Low Psychomotor Speed a
Marker of Brain Vulnerability in Late Life? Digit Symbol Substitution Test in the Prediction of
Alzheimer, Parkinson, Stroke, Disability, and Depression. *Dement Geriatr Cogn Disord*.
2019;47(4-6):297-305. doi:10.1159/000500597

547 49. Jaeger J. Digit Symbol Substitution Test: The Case for Sensitivity Over Specificity in
548 Neuropsychological Testing. J Clin Psychopharmacol. Oct 2018;38(5):513-519.
549 doi:10.1097/JCP.00000000000941

55050.Promotion NCfCDPaH. National Health Statistics Reports: Cognitive Performance in551Adults Aged 60 and Over: National Health and Nutrition Examination Survey, 2011–2014. 2019.552September17,553extension://efaidnbmnnibpcajpcglclefindmkaj/https://www.cdc.gov/nchs/data/nhsr/nhsr126-554508.pdf

555 51. Li S, Sun W, Zhang D. Association of Zinc, Iron, Copper, and Selenium Intakes with Low
556 Cognitive Performance in Older Adults: A Cross-Sectional Study from National Health and
557 Nutrition Examination Survey (NHANES). J Alzheimers Dis. 2019;72(4):1145-1157.
558 doi:10.3233/jad-190263

559 52. Chen SP, Bhattacharya J, Pershing S. Association of Vision Loss With Cognition in Older 560 Adults. *JAMA Ophthalmol.* Sep 1 2017;135(9):963-970. doi:10.1001/jamaophthalmol.2017.2838

561 53. CDC/National Center for Health Statistics. NHANES 1999-2000 Laboratory Methods.
 562 https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/labmethods.aspx?Cycle=1999-2000

563 54. CDC/National Center for Health Statistics. NHANES 2001-2002 Laboratory Methods. 564 https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/labmethods.aspx?BeginYear=2001

56555.Centers for Disease Control and Prevention. National Health Nutrition Examination566Survey(NHANES)LaboratoryProceduresManual.2011.567https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/manuals.aspx?BeginYear=2011

56856.Centers for Disease Control and Prevention. National Health Nutrition Examination569Survey (NHANES)LaboratoryProceduresManual.2013.570https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/manuals.aspx?BeginYear=2013

57. Nguyen VK, Middleton LYM, Huang L, et al. Harmonized US National Health and
572 Nutrition Examination Survey 1988-2018 for high throughput exposome-health discovery.
573 *medRxiv*. Feb 8 2023;doi:10.1101/2023.02.06.23284573

574 58. Hales CM, Carroll MD, Fryar CD, Ogden CL. *Prevalence of obesity and severe obesity* 575 *among adults: United States*, 2017–2018. NCHS Data Brief, no 360. Hyattsville, MD: National 576 Center for Health Statistics; 2020.

577 59. Kim S. Overview of Cotinine Cutoff Values for Smoking Status Classification. *Int J* 578 *Environ Res Public Health*. Dec 14 2016;13(12)doi:10.3390/ijerph13121236

579 60. National Center for Health Statistics, Centers for Disease Control and Prevention.
580 Analytic and reporting guidelines: The National Health and Nutrition Examination Survey
581 (NHANES) 2006.

61. Chung MK, Buck Louis GM, Kannan K, Patel CJ. Exposome-wide association study of
semen quality: Systematic discovery of endocrine disrupting chemical biomarkers in fertility
require large sample sizes. *Environ Int.* Apr 2019;125:505-514. doi:10.1016/j.envint.2018.11.037

585 62. Chen P, Miah MR, Aschner M. Metals and Neurodegeneration. *F1000Res*. 2016;5doi:10.12688/f1000research.7431.1

63. Olasehinde TA, Olaniran AO. Neurotoxicity of Polycyclic Aromatic Hydrocarbons: A
Systematic Mapping and Review of Neuropathological Mechanisms. *Toxics*. Jul 25
2022;10(8)doi:10.3390/toxics10080417

64. Pessah IN, Lein PJ, Seegal RF, Sagiv SK. Neurotoxicity of polychlorinated biphenyls and
related organohalogens. *Acta Neuropathol*. Sep 2019;138(3):363-387. doi:10.1007/s00401-01901978-1

593 65. Zhao Y, Chang YH, Ren HR, et al. Phthalates Induce Neurotoxicity by Disrupting the 594 Mfn2-PERK Axis-Mediated Endoplasmic Reticulum-Mitochondria Interaction. *J Agric Food* 595 *Chem.* Apr 3 2024;72(13):7411-7422. doi:10.1021/acs.jafc.3c07752

596 66. Richardson JR, Fitsanakis V, Westerink RHS, Kanthasamy AG. Neurotoxicity of pesticides. *Acta Neuropathol*. Sep 2019;138(3):343-362. doi:10.1007/s00401-019-02033-9

67. Ali H, Khan E, Ilahi I. Environmental Chemistry and Ecotoxicology of Hazardous Heavy
Metals: Environmental Persistence, Toxicity, and Bioaccumulation. J Chem-Ny.
2019;2019doi:Artn 6730305

- 601 10.1155/2019/6730305
- 602 68. Casale J, AS R. Phthalates Toxicity. *StatPearls*. 2023.

603 69. Sun K, Song Y, He F, Jing M, Tang J, Liu R. A review of human and animals exposure to 604 polycyclic aromatic hydrocarbons: Health risk and adverse effects, photo-induced toxicity and 605 regulating effect of microplastics. *Sci Total Environ*. Jun 15 2021;773:145403. 606 doi:10.1016/j.scitotenv.2021.145403

607 70. Crinnion WJ. Polychlorinated biphenyls: persistent pollutants with immunological, neurological, and endocrinological consequences. *Altern Med Rev.* Mar 2011;16(1):5-13.

Wei Y, Zhou J, Zhao F, et al. Association of blood lead exposure with frailty and its
components among the Chinese oldest old. *Ecotoxicol Environ Saf.* Sep 1 2022;242:113959.
doi:10.1016/j.ecoenv.2022.113959

612 72. Gundacker C, Forsthuber M, Szigeti T, et al. Lead (Pb) and neurodevelopment: A review
613 on exposure and biomarkers of effect (BDNF, HDL) and susceptibility. *Int J Hyg Environ Health*.
614 Sep 2021;238:113855. doi:10.1016/j.ijheh.2021.113855

615 73. Vig EK, Hu H. Lead toxicity in older adults. *J Am Geriatr Soc*. Nov 2000;48(11):1501-6.

616 74. Lv Y, Wei Y, Zhou J, et al. Human biomonitoring of toxic and essential metals in younger
617 elderly, octogenarians, nonagenarians and centenarians: Analysis of the Healthy Ageing and
618 Biomarkers Cohort Study (HABCS) in China. *Environ Int.* Nov 2021;156:106717.
619 doi:10.1016/j.envint.2021.106717

- T5. Lasley SM, Gilbert ME. Glutamatergic components underlying lead-induced impairments
 in hippocampal synaptic plasticity. *Neurotoxicology*. Dec 2000;21(6):1057-68.
- Ahamed M, Siddiqui MK. Low level lead exposure and oxidative stress: current opinions.
 Clin Chim Acta. Aug 2007;383(1-2):57-64. doi:10.1016/j.cca.2007.04.024
- Adonaylo VN, Oteiza PI. Pb2+ promotes lipid oxidation and alterations in membrane
 physical properties. *Toxicology*. Jan 1 1999;132(1):19-32. doi:10.1016/s0300-483x(98)00134-6

78. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and
cardiovascular disease--a systematic review. *Environ Health Perspect*. Mar 2007;115(3):472-82.
doi:10.1289/ehp.9785

80. Ge S, Ma W, Qu Z, et al. Urinary tobacco-specific nitrosamine 4-(methylnitrosamino)-1-632 (3-pyridyl)-1-butanol (NNAL) and cognitive functioning in older adults: The National Health 633 634 and Nutrition Examination Survey 2013-2014. Tob Induc Dis. 2023;21:68. doi:10.18332/tid/162368 635

81. Yalcin E, de la Monte S. Tobacco nitrosamines as culprits in disease: mechanisms
reviewed. *J Physiol Biochem*. Mar 2016;72(1):107-20. doi:10.1007/s13105-016-0465-9

82. Bovet L, Campanoni P, Lu J, et al. CLCNt2 Mediates Nitrate Content in Tobacco Leaf,
Impacting the Production of Tobacco-Specific Nitrosamines in Cured Leaves. *Front Plant Sci.*2022;13:741078. doi:10.3389/fpls.2022.741078

83. Boo HJ, Min HY, Hwang SJ, et al. The tobacco-specific carcinogen NNK induces
pulmonary tumorigenesis via nAChR/Src/STAT3-mediated activation of the renin-angiotensin
system and IGF-1R signaling. *Exp Mol Med.* Jun 2023;55(6):1131-1144. doi:10.1038/s12276023-00994-2

84. Dubey D, Sharma VD, Pass SE, Sawhney A, Stuve O. Para-dichlorobenzene toxicity - a
review of potential neurotoxic manifestations. *Ther Adv Neurol Disord*. May 2014;7(3):177-87.
doi:10.1177/1756285614521889

648 85. Budny JA. Encyclopedia of Toxicology, 3rd edition. *Int J Toxicol*. Jul-Aug 2015;34(4):366-367. doi:10.1177/1091581815586498

86. Suhua W, Rongzhu L, Changqing Y, et al. Lipid peroxidation and changes of trace
elements in mice treated with paradichlorobenzene. *Biol Trace Elem Res.* Sep 2010;136(3):32036. doi:10.1007/s12011-009-8552-1

653 87. Oikawa S, Kawanishi S. Copper-mediated DNA damage by metabolites of p-654 dichlorobenzene. *Carcinogenesis*. Dec 1996;17(12):2733-9. doi:10.1093/carcin/17.12.2733

88. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of
stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. *Lancet*. Jan
18 2014;383(9913):245-54. doi:10.1016/s0140-6736(13)61953-4

89. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. *Curr Med Chem*.
2005;12(10):1161-208. doi:10.2174/0929867053764635

Al-Qazzaz NK, Ali SH, Ahmad SA, Islam S, Mohamad K. Cognitive impairment and
 memory dysfunction after a stroke diagnosis: a post-stroke memory assessment. *Neuropsychiatr Dis Treat*. 2014;10:1677-91. doi:10.2147/NDT.S67184

663 91. Cullen B, O'Neill B, Evans JJ, Coen RF, Lawlor BA. A review of screening tests for
664 cognitive impairment. J Neurol Neurosurg Psychiatry. Aug 2007;78(8):790-9.
665 doi:10.1136/jnnp.2006.095414

666 92. Carreras G, Miccinesi G, Wilcock A, et al. Missing not at random in end of life care 667 studies: multiple imputation and sensitivity analysis on data from the ACTION study. *BMC Med* 668 *Res Methodol*. Jan 9 2021;21(1):13. doi:10.1186/s12874-020-01180-y

669